Publication Title
The Journal of clinical investigation
Document Type
Article
Publication Date
6-17-2019
Keywords
Animals; Docosahexaenoic Acids; Immunity, Cellular; Ketorolac; Male; Mice; Mice, Knockout; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms, Experimental; Preoperative Care; T-Lymphocytes
Abstract
Cancer therapy is a double-edged sword, as surgery and chemotherapy can induce an inflammatory/immunosuppressive injury response that promotes dormancy escape and tumor recurrence. We hypothesized that these events could be altered by early blockade of the inflammatory cascade and/or by accelerating the resolution of inflammation. Preoperative, but not postoperative, administration of the nonsteroidal antiinflammatory drug ketorolac and/or resolvins, a family of specialized proresolving autacoid mediators, eliminated micrometastases in multiple tumor-resection models, resulting in long-term survival. Ketorolac unleashed anticancer T cell immunity that was augmented by immune checkpoint blockade, negated by adjuvant chemotherapy, and dependent on inhibition of the COX-1/thromboxane A2 (TXA2) pathway. Preoperative stimulation of inflammation resolution via resolvins (RvD2, RvD3, and RvD4) inhibited metastases and induced T cell responses. Ketorolac and resolvins exhibited synergistic antitumor activity and prevented surgery- or chemotherapy-induced dormancy escape. Thus, simultaneously blocking the ensuing proinflammatory response and activating endogenous resolution programs before surgery may eliminate micrometastases and reduce tumor recurrence.
Area of Special Interest
Cancer
Specialty/Research Institute
Institute for Systems Biology
Specialty/Research Institute
Oncology
